Local drug and gene delivery through microbubbles

被引:269
作者
Unger, EC
Hersh, E
Vannan, M
Matsunaga, TO
McCreery, M
机构
[1] Univ Arizona, Dept Radiol, Arizona Canc Ctr, Tucson, AZ 85724 USA
[2] Med Coll Penn & Hahnemann Univ, Philadelphia, PA USA
[3] ImaRx Therapeut Inc, Tucson, AZ USA
关键词
D O I
10.1053/pcad.2001.26443
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ultrasound contrast agents (microbubbles) lower the threshold for cavitation by ultrasound energy. Ultrasound microbubbles may be used as cavitation nuclei for drug and gene delivery. By tailoring the physical properties of microbubbles and coating materials, drugs and genetic drugs can be incorporated into ultrasound contrast agents. As the microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing the therapeutic agents. Cavitation also causes a local shockwave that improves cellular uptake of the therapeutic agent. As a result of the human genome project and continuing advances in molecular biology, many therapeutic genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve myocardial vascularization and ameliorate congestive heart failure. For successful development of clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents can be used to develop new, more effective vectors for gene delivery. Transthoracic ultrasound can be focused on the heart so that an intravenous injection of gene-bearing microbubbles will deliver genes relatively selectively to the myocardium. Using this technique, we have produced high levels of transgene expression in the insonated region of the myocardium. This new technology, using microbubbles and ultrasound for drug and gene delivery, merits further study and development. © 2001 by W.B. Saunders Company.
引用
收藏
页码:45 / 54
页数:10
相关论文
共 50 条
[1]   Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine [J].
Anwer, K ;
Shi, M ;
French, MF ;
Muller, SR ;
Chen, W ;
Liu, QS ;
Proctor, BL ;
Wang, JJ ;
Mumper, RJ ;
Singhal, A ;
Rolland, AP ;
Alila, HW .
HUMAN GENE THERAPY, 1998, 9 (05) :659-670
[2]   GAUGING THE LIKELIHOOD OF CAVITATION FROM SHORT-PULSE, LOW-DUTY CYCLE DIAGNOSTIC ULTRASOUND [J].
APFEL, RE ;
HOLLAND, CK .
ULTRASOUND IN MEDICINE AND BIOLOGY, 1991, 17 (02) :179-185
[3]   Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia [J].
Baumgartner, I ;
Pieczek, A ;
Manor, O ;
Blair, R ;
Kearney, M ;
Walsh, K ;
Isner, JM .
CIRCULATION, 1998, 97 (12) :1114-1123
[4]   Assessment of myocardial perfusion by intermittent harmonic power Doppler using SonoVue, a new ultrasound contrast agent [J].
Broillet, A ;
Puginier, J ;
Ventrone, R ;
Schneider, M .
INVESTIGATIVE RADIOLOGY, 1998, 33 (04) :209-215
[5]  
CAPILCE NM, 1999, INT J CARDIOVASC INT, V2, P141
[6]   Immune modulation by IL-10 gene transfer via viral vector and plasmid DNA: Implication for gene therapy [J].
Chun, S ;
Daheshia, M ;
Lee, S ;
Rouse, BT .
CELLULAR IMMUNOLOGY, 1999, 194 (02) :194-204
[7]  
COSGROVE DO, 1999, TXB CONTRAST MEDIA, P451
[8]  
Ernst H, 1996, J CLIN ULTRASOUND, V24, P31, DOI 10.1002/(SICI)1097-0096(199601)24:1<31::AID-JCU5>3.0.CO
[9]  
2-M
[10]   A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine:: Effect of molecular weight on transfection efficiency and cytotoxicity [J].
Fischer, D ;
Bieber, T ;
Li, YX ;
Elsässer, HP ;
Kissel, T .
PHARMACEUTICAL RESEARCH, 1999, 16 (08) :1273-1279